Contrast-enhanced CT scan is the standard staging modality for patients with bladder cancer undergoing radical cystectomy (RC). Involvement of lymph nodes (LN) determines prognosis of patients with bladder cancer.
Urothelial carcinomas (UC), also known as transitional cell carcinomas, account for the majority of upper urinary tract tumors. The gold-standard therapy for operable patients with localized disease is radical nephroureterectomy.
The European Association of Urology (EAU) has updated its guidelines on sexual and reproductive health for 2021. To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health, including advances and areas of controversy in male infertility.
Diane K. Newman: Welcome. I’m Diane Newman. I’m a nurse practitioner at the University of Pennsylvania in the Division of Urology, and I’m here today as one of the editors at UroToday.com, interviewing an expert in the area of hypertension. I want to introduce to you, Dr. Michael Weber, he is a Professor of Medicine […]
(UroToday.com) The 2021 European Society of Medical Oncology’s (EMSO) annual congress included a proffered paper session in non-prostate genitourinary tumors, as well as a discussant presentation by Dr. Brian Rini discussing maintaining efficacy and improving quality of life in the delivery of RCC therapy. Dr. Rini discussed three excellent abstracts: “Pembrolizumab versus placebo as adjuvant therapy […]
(UroToday.com) In this presentation, Dr. Daniel Petrylak discussed results from the final analysis of CheckMate 9KD Cohort A2. This single-arm study evaluated the clinical activity of nivolumab plus rucaparib in men with metastatic castration-resistant prostate cancer (mCRPC) previously untreated with chemotherapy or PARP inhibitor. Patients eligible for Cohort A2 were not candidates for or refused chemotherapy. […]
(UroToday.com) In this presentation, Dr. Mark Markowski discussed results of a Phase 1b/2 study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA). Sabizabulin is an oral agent that inhibits microtubule assembly as well as disrupts androgen receptor transport from […]
(UroToday.com) In this presentation, Dr. Richard Cathomas presented results from SAKK 08/16, a randomized double-blind placebo-controlled phase II trial of darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane. This study sought to assess whether an immediate switch to darolutamide […]
(UroToday.com) In this study, Dr. Karim Fizazi discussed the health-related quality of life (HRQoL) data from the VISION study of 177Lu-PSMA-617 (Lu-PSMA). While the results of the VISION study, published earlier this year, demonstrated a significant improvement in radiographic progression-free survival (rPFS) and overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC), this is […]
(UroToday.com) In this presentation, Dr. Eleni Efstathiou, discussed two oral abstracts from the Presidential Symposium: 1) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol (LBA4PR) […]
